Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
about
Benzodiazepines for generalised anxiety disorder (GAD)Duloxetine versus other anti-depressive agents for depressionTreating comorbid anxiety and depression: Psychosocial and pharmacological approachesPotential drug-drug interactions in Alzheimer patients with behavioral symptomsCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersInvestigational drugs for treating agitation in persons with dementia.Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): study protocol for a cluster-randomised controlled trialSystematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series.Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011Use of antipsychotic medications in pediatric populations: what do the data say?Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study.Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Antipsychotic use among nursing home residentsDiscovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish.The psychoactive effects of psychiatric medication: the elephant in the room.Safety of low doses of quetiapine when used for insomnia.Doing Damage in Delirium: The Hazards of Antipsychotic Treatment in Elderly Persons.The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugsAtypical antipsychotics as a possible treatment option for irritable bowel syndrome.Consensus and variations in opinions on delirium care: a survey of European delirium specialistsA pharmacy led program to review anti-psychotic prescribing for people with dementia.State Investments in Psychiatric Innovation: Investigating Unmeasured State Factors.Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials.Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.Effects of quetiapine treatment on cocaine self-administration and behavioral indices of sleep in adult rhesus monkeys.Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study.Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design.Antipsychotics and mortality: adjusting for mortality risk scores to address confounding by terminal illness.Evaluation and management of the elderly patient presenting with cognitive complaints.Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysisAtypical antipsychotics for older adults: are they safe and effective as we once thought?Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort studyPseudoaldosteronism induced by Yokukansan in an elderly Japanese type 2 diabetic patient with Alzheimer's disease.On-label and off-label use of high-dose influenza vaccine in the United States, 2010-2012Effect of an interactive therapeutic robotic animal on engagement, mood states, agitation and psychotropic drug use in people with dementia: a cluster-randomised controlled trial protocol.A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder.Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force.Issues around the Prescription of Half Tablets in Northern Switzerland: The Irrational Case of Quetiapine.Diagnosis and management of behavioral issues in frontotemporal dementia
P2860
Q24197945-D3AA1945-F9C4-404E-8F51-BC429DA673FAQ24198808-561B110F-B161-493F-BE18-DBFEE623D895Q26770334-809EDB39-F0C9-4FEE-976E-C5D2734E90A5Q26782490-DCCF0A3C-E841-41DA-A3D5-42AAE39972D3Q27009995-5BBF1AC2-9F18-4A91-8D02-2C52ACB2693BQ30250076-675211A0-B6AC-4BB6-920D-206E3B7A7F3BQ30316492-9E8A9A64-B4D8-456C-9D05-278136E65E65Q30400013-A2041344-1BD9-4EE9-ABC5-CF8C599D6EB0Q30650589-3CF356B8-1C5A-4BA7-AF13-870F1E68ADB6Q30698390-8B119230-2A47-4B81-814A-3FCE8A2AF6B5Q33736204-E37C53AF-E010-44AA-9CBA-363BCFED762DQ33878816-4CB70C4F-DD0A-479E-9A73-B5AF4C35FADEQ33924005-DC5096F5-D50D-4E3E-BB72-7D6FE3E3FA1EQ33943741-FC1A3672-D8F7-45AA-A29A-B2B83D25F756Q33989385-2D490D47-D5AD-43BE-8D16-E50A3890EBD6Q34031523-EC9BCBD5-48E2-468A-847C-7CD5F7F9028DQ34267707-B2109C1C-B608-46EC-AFBB-CA4DA4DC3901Q34300560-BD51D64F-FAA4-466B-8E37-A4C636DE2C92Q34333642-F7B3EB16-E89E-4AF3-9394-B1AE8562549BQ34365410-117D1A21-009B-4346-85E7-7777512B1B5EQ34420206-31C94709-1EBB-43EF-A8D0-0C86B6D65144Q34482769-F2EDBBB6-5BBB-4FC3-80FF-9A6D992FB8D2Q34566324-080CE96A-65F5-4A3E-8BA4-40CC19FCD390Q34646095-11E6A5A9-8FED-4D9D-B3D3-DFB46658D555Q34979796-51F76B7D-7D20-4131-9B4B-0740712DB6B4Q35087495-EAE30CE0-51D7-4B26-AD00-461751E8D8C6Q35185368-B8F34953-715D-45DD-A73F-1D773AF53A75Q35217862-BF6CF62D-368A-402B-8636-512C084A4278Q35447239-32A59C43-1F92-4C93-B83F-492EC736E371Q35499945-2F437315-FAE2-4191-9048-05880172819BQ35565618-492C6572-3DEF-4325-B95D-211632245A1DQ35630897-9BFB69AF-DF4B-401C-8C3C-9A67C351B90FQ35775454-EEE5B098-C95D-4A28-8431-6A77D5AC7B13Q35879352-4CC53253-A200-433D-B6C4-43D2EC3631FAQ35887048-DB168402-D5B1-4BDD-B945-D492D1A6036DQ35960104-99CDE535-D701-459A-8CC9-3573E2F00141Q36062173-8188B743-0443-4528-B094-E863383C4017Q36087892-1A75542B-4157-43C5-BF88-2DC468C98AA6Q36204126-7566DE66-1B3C-47DC-9B33-01D26B17C3C2Q36238717-75B95881-2955-468E-A2DB-FA7A1A5E4815
P2860
Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy and comparative effec ...... atic review and meta-analysis.
@ast
Efficacy and comparative effec ...... atic review and meta-analysis.
@en
Efficacy and comparative effec ...... atic review and meta-analysis.
@nl
type
label
Efficacy and comparative effec ...... atic review and meta-analysis.
@ast
Efficacy and comparative effec ...... atic review and meta-analysis.
@en
Efficacy and comparative effec ...... atic review and meta-analysis.
@nl
prefLabel
Efficacy and comparative effec ...... atic review and meta-analysis.
@ast
Efficacy and comparative effec ...... atic review and meta-analysis.
@en
Efficacy and comparative effec ...... atic review and meta-analysis.
@nl
P2093
P356
P1476
Efficacy and comparative effec ...... atic review and meta-analysis.
@en
P2093
Alicia Ruelaz Maher
Brett Ewing
David Sultzer
Jian-Hui Hu
Margaret Maglione
Marika Suttorp
Martha Timmer
Paul G Shekelle
Steven Bagley
P304
P356
10.1001/JAMA.2011.1360
P407
P50
P577
2011-09-01T00:00:00Z